Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases. The company focuses on providing innovative medicines in haematology, immunology, and specialty care. With approximately 1,800 employees, Sobi operates across Europe, North America, the Middle East, Asia, and Australia. In 2024, Sobi reported a revenue of SEK 26 billion and is publicly traded on Nasdaq Stockholm under the ticker STO:SOBI.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueIncludes treatments for haemophilia and related conditions
Comprises medicines for immune system disorders
Focuses on rare diseases and niche therapeutic areas
Customers
Sobi serves a diverse range of customers, primarily focusing on healthcare providers and institutions that treat rare and debilitating diseases. The company's products are used by hospitals, specialized clinics, and healthcare professionals who manage patients with complex medical conditions. Sobi's customer base is global, with significant presence in Europe, North America, and emerging markets. The company aims to provide reliable access to innovative therapies, addressing unmet medical needs and improving patient outcomes.
Hospitals and clinics purchasing treatments for rare diseases
Focused on haemophilia and immunology treatments
Growing demand for innovative therapies
Strategy
Sobi's strategic priorities include expanding its portfolio of innovative therapies and increasing its market presence in key regions. The company is focused on strengthening its leadership in haemophilia through new product launches and strategic acquisitions. Sobi aims to enhance its R&D capabilities to accelerate the development of new treatments for rare diseases. The company is also committed to optimizing its go-to-market model and building strong relationships with healthcare professionals and institutions.
To address unmet medical needs
To capture market share
To accelerate new treatment development
Geography
Sobi operates globally, with a strong presence in Europe, North America, and expanding markets in the Middle East, Asia, and Australia. The company's headquarters are located in Stockholm, Sweden. Sobi's geographic reach allows it to address diverse healthcare needs and regulatory environments, enhancing its ability to deliver innovative treatments worldwide. The company's strategic focus on expanding its market share in Europe and North America is complemented by its efforts to enter new markets in Asia and the Middle East.
Risks
Sobi faces several risks, including regulatory changes, competitive pressures, and the inherent uncertainties of drug development. The company's reliance on a limited number of key products exposes it to market fluctuations and competitive threats. Additionally, geopolitical risks in regions like China could impact supply chains and market access. The biopharmaceutical industry is also subject to stringent regulatory requirements, which can affect product approvals and market entry.
Impacts supply chains and market access
Exposure: China
Can delay product approvals
Affects market share and pricing
Accounting
Judgemental itemsAffects quarterly financial results
Impact: high
Significantly impact reported earnings
Impact: medium
Similar listed companies
Publicly listed companies with a comparable business focus.
SEB
SEB-A · Financials
Saab AB is a Swedish high-technology company specializing in defense, aviation, and civil security.
Alvotech SDB
ALVO-SDB · Health Care
Alvotech SDB is the Swedish depositary receipt of Alvotech, an Iceland-based biopharmaceutical company focused on developing and manufacturing biosimilar medicines.
Sanofi
SNY · Pharmaceutical Preparations
Sanofi is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines and vaccines.
Apellis Pharmaceuticals, Inc.
Pharmaceutical Preparations
Apellis Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company built around complement inhibition, with pegcetacoplan as its core molecule.
Oncopeptides
ONCO · Health Care
Oncopeptides is a Swedish biopharmaceutical company focused on developing and commercializing therapies for difficult-to-treat hematological diseases.
BioInvent International
BINV · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
Last updated: 24/09/2026